Importance of Neuraminidase Active-Site Residues to the Neuraminidase Inhibitor Resistance of Influenza Viruses

Resistance of influenza viruses to neuraminidase inhibitors--a review.

Influenza virus is a negative stranded RNA virus. It contains two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). HA exists as a trimer and is responsible for binding to the terminal sialic acid bound to receptors on the surface of the target cell, leading to attachment and subsequent penetration by the virus into the cell. Influenza virus isolates from different animals appea...

Influenza viruses resistant to neuraminidase inhibitors.

Neuraminidase inhibitors (NAIs) are antiviral drugs for treatment and prophylaxis of influenza. By blocking the activity of the enzyme neuraminidase, NAIs prevent new viral particles from being released. The increasing use of NAIs brings into focus the risk of drug resistance arising to the class. There are three levels of antiviral resistance according to the way that resistance can be detecte...

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

The neuraminidase (NA) inhibitors are the only class of antivirals approved for the treatment and prophylaxis of influenza that are effective against currently circulating strains. In addition to their use in treating seasonal influenza, the NA inhibitors have been stockpiled by a number of countries for use in the event of a pandemic. It is therefore important to monitor the susceptibility of ...

HPA Guidance for Neuraminidase Inhibitor Resistance testing of Influenza B and A(H3N2) viruses

Influenza B Viruses with Mutation in the Neuraminidase Active Site, North Carolina, USA, 2010–11

Oseltamivir is 1 of 2 antiviral medications available for the treatment of influenza B virus infections. We describe and characterize a cluster of influenza B viruses circulating in North Carolina with a mutation in the neuraminidase active site that may reduce susceptibility to oseltamivir and the investigational drug peramivir but not to zanamivir.